BetterLife Pharma Inc. (CSE: BETR)
Canada
· Delayed Price · Currency is CAD
0.105
0.00 (0.00%)
Dec 19, 2024, 9:30 AM EST
BetterLife Pharma Income Statement
Financials in millions CAD. Fiscal year is February - January.
Millions CAD. Fiscal year is Feb - Jan.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 | Jan '21 Jan 31, 2021 | Jan '20 Jan 31, 2020 | 2019 - 2015 |
Cost of Revenue | - | - | - | - | 0.02 | 0.09 | Upgrade
|
Gross Profit | - | - | - | - | -0.02 | -0.09 | Upgrade
|
Selling, General & Admin | 4.1 | 2.64 | 6.56 | 4.53 | 7.56 | 7.8 | Upgrade
|
Research & Development | 0.7 | 0.57 | 2.68 | 5.42 | 0.28 | 0.06 | Upgrade
|
Other Operating Expenses | - | - | - | - | - | 0.02 | Upgrade
|
Operating Expenses | 4.81 | 3.21 | 9.26 | 9.97 | 7.93 | 9.24 | Upgrade
|
Operating Income | -4.81 | -3.21 | -9.26 | -9.97 | -7.95 | -9.32 | Upgrade
|
Interest Expense | -0.32 | -0.05 | -0.07 | -0.06 | -0.04 | -0.43 | Upgrade
|
Interest & Investment Income | - | - | - | - | 0 | 0 | Upgrade
|
Currency Exchange Gain (Loss) | -0.16 | -0.03 | -0.2 | -0.24 | 0.04 | -0.04 | Upgrade
|
Other Non Operating Income (Expenses) | 0.2 | -0.17 | -0 | -1.07 | -0.3 | 0.05 | Upgrade
|
EBT Excluding Unusual Items | -5.08 | -3.46 | -9.53 | -11.33 | -8.25 | -9.74 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | - | 0.19 | -15.86 | -1.3 | Upgrade
|
Asset Writedown | - | - | - | - | -12.12 | -6.63 | Upgrade
|
Legal Settlements | 0.13 | 0.13 | 0.26 | -0.56 | -0.12 | -0.26 | Upgrade
|
Other Unusual Items | 0.55 | 0.44 | -0.1 | -0.29 | - | -1.65 | Upgrade
|
Pretax Income | -4.4 | -2.9 | -9.37 | -11.99 | -36.35 | -19.59 | Upgrade
|
Income Tax Expense | - | - | - | 0.17 | - | - | Upgrade
|
Earnings From Continuing Operations | -4.4 | -2.9 | -9.37 | -12.16 | -36.35 | -19.59 | Upgrade
|
Minority Interest in Earnings | -0.48 | 0.01 | 0.36 | - | - | - | Upgrade
|
Net Income | -4.88 | -2.89 | -9.02 | -12.16 | -36.35 | -19.59 | Upgrade
|
Net Income to Common | -4.88 | -2.89 | -9.02 | -12.16 | -36.35 | -19.59 | Upgrade
|
Shares Outstanding (Basic) | 116 | 109 | 87 | 75 | 27 | 15 | Upgrade
|
Shares Outstanding (Diluted) | 116 | 109 | 87 | 75 | 27 | 15 | Upgrade
|
Shares Change (YoY) | 20.64% | 26.25% | 14.70% | 179.24% | 79.75% | 66.69% | Upgrade
|
EPS (Basic) | -0.04 | -0.03 | -0.10 | -0.16 | -1.34 | -1.30 | Upgrade
|
EPS (Diluted) | -0.04 | -0.03 | -0.10 | -0.16 | -1.34 | -1.30 | Upgrade
|
Free Cash Flow | -2.51 | -2.47 | -1.5 | -11.2 | -7.18 | -8.42 | Upgrade
|
Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.15 | -0.27 | -0.56 | Upgrade
|
EBITDA | - | -3.19 | -9.24 | -9.95 | -7.8 | -8.34 | Upgrade
|
D&A For EBITDA | - | 0.02 | 0.02 | 0.02 | 0.16 | 0.99 | Upgrade
|
EBIT | -4.81 | -3.21 | -9.26 | -9.97 | -7.95 | -9.32 | Upgrade
|
Advertising Expenses | - | - | 0.12 | 0.44 | 0.19 | 0.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.